Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$2.23 and traded as high as C$2.40. Aptose Biosciences shares last traded at C$2.40, with a volume of 1,605 shares traded.

Aptose Biosciences Price Performance

The company has a debt-to-equity ratio of -103.31, a quick ratio of 5.41 and a current ratio of 0.69. The stock has a market capitalization of C$6.12 million, a price-to-earnings ratio of 3.48 and a beta of -1.29. The company has a 50-day moving average of C$2.23 and a 200-day moving average of C$2.08.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its earnings results on Tuesday, March 31st. The biotechnology company reported C($4.07) EPS for the quarter. As a group, equities research analysts expect that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.